Roche's Breakthrough Blood Test for Alzheimer's Receives FDA Designation

2 min read | April 12, 2024 07:27 AM AEST | By Team Kalkine Media

Google News:

Roche's Breakthrough Blood Test for Alzheimer's Receives FDA Designation — Image source: shutterstock

Recent News

ASX Rally Watch Builds as RBA Decision Nears in Focus

CSL Outlook Shift After Impairments Raises Fresh Debate

Santos LNG And Pikka Expansion Drive Focus on ASX 300 Energy Sector Sh...

APA Group Gas Strategy Shift Reshapes Energy Outlook

Make Kalkine Media
My Trusted Source

Roche (SIX: RO, ROG; OTCQX: RHHBY), with over 20 years of dedicated scientific research in Alzheimer's disease, is committed to advancing detection methods and treatments to combat this debilitating condition. With a vision of early detection and halting disease progression, Roche's Alzheimer's portfolio encompasses investigational medicines targeting various aspects of the disease.

In a significant development, Roche has announced that its Elecsys pTau217 assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Developed in collaboration with Eli Lilly and Company, this blood test aims to identify the presence or absence of amyloid pathology in individuals, facilitating timely and accurate diagnosis.

The availability of such a blood test could revolutionize Alzheimer's diagnosis by enabling healthcare providers to identify the disease at an early stage. This early detection may allow individuals to access appropriate care, including enrollment in clinical trials or the use of approved disease-modifying therapies. By facilitating prompt diagnosis and intervention, the test has the potential to alleviate the burden of Alzheimer's disease on individuals and society.

Roche and Lilly, as leaders in Alzheimer's innovation, aspire to accelerate testing and diagnosis through their collaboration. By combining their expertise and resources, they aim to enhance the speed and scale of diagnostic solutions in this critical area of unmet medical need.

In conclusion, Roche's breakthrough blood test represents a significant milestone in the fight against Alzheimer's disease. With the potential to revolutionize diagnosis and treatment, this innovative assay holds promise for transforming the lives of millions affected by this devastating condition. As Roche and Lilly continue to collaborate and innovate, there is renewed hope for a future where Alzheimer's disease can be detected early and its progression halted, preserving the essence of what makes individuals who they are.

Roche shares closed 1.21% higher at USD 30.96 apiece on 11 April 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.